PROPELLON THERAPEUTICS
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.
PROPELLON THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2016-06-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Total Employee:
1+
Status:
Active
Total Funding:
3 M USD
Similar Organizations
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Employees Featured
Investors List
Jed McCaleb
Jed McCaleb investment in Seed Round - Propellon Therapeutics
FACIT
FACIT investment in Seed Round - Propellon Therapeutics
Dan Schultz
Dan Schultz investment in Seed Round - Propellon Therapeutics
Rami Essaid
Rami Essaid investment in Seed Round - Propellon Therapeutics
More informations about "Propellon Therapeutics"
Propellon Company Profile 2024: Valuation, Investors, Acquisition ...
Information on acquisition, funding, cap tables, investors, and executives for Propellon. Use the PitchBook Platform to explore the full profile.See details»
FACIT Announces Investment in Propellon Therapeutics
TORONTO, ON (March 22, 2017) – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on …See details»
First-in-class drug for blood cancers discovered by …
Jan 29, 2019 Once the potential of WDR5 was realized, FACIT quickly provided tools and services to move the project along, including the establishment of a start-up company called Propellon Therapeutics and providing Propellon with …See details»
Propellon Therapeutics to Accelerate WDR5 Inhibitor …
FACIT has announced the creation of a new Ontario biotechnology company, Propellon Therapeutics Inc. (“Propellon” or “the Company”), to manage the development and …See details»
FACIT and Triphase Accelerator Announce New Partnership with …
FACIT seed financed Propellon Therapeutics to commercialize the preclinical asset and ran a competitive global business development process to identify strategic partners. Multiple formal …See details»
New potential treatment for leukemia discovered by …
Jan 29, 2019 FACIT provided the project with a commercialization strategy, spun out a company called Propellon Therapeutics, and provided the necessary seed capital to resource, support and accelerate the project.See details»
Propellon Therapeutics Inc - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Propellon Therapeutics Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Propellon Therapeutics - Funding, Financials, Valuation & Investors
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein.See details»
Propellon Therapeutics to Accelerate WDR5 Inhibitor ... - Newswire
Jun 23, 2016 Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and …See details»
FACIT Announces Investment in Propellon Therapeutics
TORONTO, March 22, 2017 /CNW/ – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer …See details»
Propellon Therapeutics Inc - Company Profile and News
Propellon Therapeutics Inc operates as a pharmaceutical company. The Company discovers, commercializes, and develops novel cancer therapies for the treatment of patients.See details»
Propellon Therapeutics - CB Insights
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone …See details»
Propellon Therapeutics - Ontario Institute for Cancer Research
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.See details»
FACIT Announces Investment in Propellon Therapeutics - PR …
TORONTO, March 22, 2017 /PRNewswire/ - FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by FACIT focused …See details»
Propellon Therapeutics - Crunchbase
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein.See details»
FACIT Announces Investment in Propellon Therapeutics - Newswire
TORONTO, March 22, 2017 /CNW/ - FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by FACIT focused on …See details»
FACIT recognized with 2020 Venture Capital Regional Impact …
Jun 9, 2020 FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics (“Propellon”) and Triphase …See details»
Propellon Therapeutics - Tech Stack, Apps, Patents & Trademarks
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein.See details»
Research programme: WDR5 inhibitors - Propellon …
Propellon Therapeutics and Ontario Institute for Cancer Research are developing WDR5 inhibitors for the treatment of cancer. The WDR5 protein is critical forSee details»